Partnering Strategy
Open to range of models, Global & Regional Deals, JV, Spin-Offs and Optional Deal Arrangements.
Explore commercialization opportunities across 'pharmerging' markets on our own or with partners
In License differentiated pre-clinical/IND stage assets and progress them through clinical POC/Phase II
Explore co-development opportunities with assets that complement Rhizen programs
Support CMC development and commercial supply activities
Monetize our inflammation assets through global out-licensing to partners with deep TA expertise
Our Partners
TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. TG Therapeutics is headquartered in New York City (www.tgtxinc.com)
Curon Biopharmaceutical, founded in June 2018, is a biopharma company with facility in Shanghai focusing on developing next generation anti-cancer therapies
A Template of Our Win-Win Partnering Strategy
Journey from discovery to advanced clinical development – Asset Centric
Prospective and flexible partnerships through discovery to early development
- Partner to exercise rights for regional/global rights
- Rhizen to extend full transitional support to maximize development vs patent life
Focused developmental support
from Rhizen
- Rhizen extends CMC development, GMP based clinical supplies and commercial production
- Active alliance management to facilitate data generation through NDA filing
Alliance to focus on best utilization of respective capabilities with Rhizen’s proven track record
